000296131 001__ 296131
000296131 005__ 20250425083857.0
000296131 0247_ $$2doi$$a10.1002/ijc.35322
000296131 0247_ $$2pmid$$apmid:39751766
000296131 0247_ $$2ISSN$$a0020-7136
000296131 0247_ $$2ISSN$$a1097-0215
000296131 037__ $$aDKFZ-2025-00061
000296131 041__ $$aEnglish
000296131 082__ $$a610
000296131 1001_ $$0P:(DE-He78)772c4cbbab31f1b71f814e8ae9e0ed51$$aSergeev, Dmitry$$b0$$eFirst author$$udkfz
000296131 245__ $$aPotential for enhancing efficacy of screening colonoscopy by lowering starting ages and extending screening intervals: A modelling study for Germany.
000296131 260__ $$aBognor Regis$$bWiley-Liss$$c2025
000296131 3367_ $$2DRIVER$$aarticle
000296131 3367_ $$2DataCite$$aOutput Types/Journal article
000296131 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1745563079_21577
000296131 3367_ $$2BibTeX$$aARTICLE
000296131 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000296131 3367_ $$00$$2EndNote$$aJournal Article
000296131 500__ $$a#EA:C070#LA:C070# / Volume 156, Issue12, 15 June 2025, Pages 2303-2310
000296131 520__ $$aStudies aimed to evaluate the expected impact of alternative screening strategies are essential for optimizing colorectal cancer (CRC) screening offers, but such studies are lacking in Germany, where two screening colonoscopies (CS) 10 years apart are offered for men from age 50 and women from age 55. Our aim was to explore whether and to what extent the efficacy of utilizing two CS could be enhanced by alternative starting ages and screening intervals. We modeled the expected numbers of CRC cases, CRC deaths, years of potential life lost (YPLL), and disability-adjusted life years (DALYs) due to CRC in hypothetical cohorts of 100,000 men and women aged 45-85 using COSIMO, a validated Markov-based multi-state simulation model. Modeled strategies included combinations of starting ages (45/50/55/60) and CS (10/15/20 years). For men, CRC deaths could be slightly reduced by extending the interval to 15 years, with a second CS at 65. YPLL and DALYs would be reduced by decreasing starting age to 45 when combined with a 15-year screening interval. For women, use of two CS at ages 50 and 65 would reduce all CRC burden parameters compared to the current earliest-use offer at 55 and 65 years. Our results suggest that lowering the starting age of screening colonoscopy to 45 for men and 50 for women, combined with extending the CS screening interval to 15 years would have the potential to enable significant reductions in years of potential life lost, and disability-adjusted life years compared to current screening offers in Germany.
000296131 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000296131 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000296131 650_7 $$2Other$$acolonoscopy
000296131 650_7 $$2Other$$acolorectal cancer
000296131 650_7 $$2Other$$aendoscopy
000296131 650_7 $$2Other$$amodelling
000296131 650_7 $$2Other$$ascreening
000296131 7001_ $$0P:(DE-HGF)0$$aHeisser, Thomas$$b1
000296131 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b2$$udkfz
000296131 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b3$$eLast author$$udkfz
000296131 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.35322$$gp. ijc.35322$$n12$$p2303-2310$$tInternational journal of cancer$$v156$$x0020-7136$$y2025
000296131 909CO $$ooai:inrepo02.dkfz.de:296131$$pVDB
000296131 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)772c4cbbab31f1b71f814e8ae9e0ed51$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000296131 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000296131 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000296131 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000296131 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000296131 9141_ $$y2025
000296131 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
000296131 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2023-10-21$$wger
000296131 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000296131 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000296131 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000296131 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000296131 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000296131 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000296131 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000296131 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-21
000296131 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000296131 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2022$$d2023-10-21
000296131 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2022$$d2023-10-21
000296131 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000296131 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000296131 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000296131 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000296131 980__ $$ajournal
000296131 980__ $$aVDB
000296131 980__ $$aI:(DE-He78)C070-20160331
000296131 980__ $$aI:(DE-He78)HD01-20160331
000296131 980__ $$aUNRESTRICTED